AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31081694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirasemtiv (125 mg twice daily)
Number of subjects: 744
Study 31081694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 744
Study 31081694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirasemtiv (tolerated dose)
Number of subjects: 744
Study 31081694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirasemtiv
Number of subjects: 744
Study 28941810 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification for Hostility (IBM‐H)
Number of subjects: 58
Study 28941810 — intervention group
Group type: COMPARATOR
Intervention: Healthy Video Control (HVC)
Number of subjects: 58
Study 26376753 — intervention group
Group type: EXPERIMENTAL
Intervention: Granular group (preference-setting tool)
Number of subjects: 2718
Study 26376753 — intervention group
Group type: COMPARATOR
Intervention: None group
Number of subjects: 2718
Study 26376753 — intervention group
Group type: EXPERIMENTAL
Intervention: All group
Number of subjects: 2718
Study 26376753 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary group
Number of subjects: 2718
Study 22875659 — intervention group
Group type: EXPERIMENTAL
Intervention: uKIM‐1 in preterm infants with RDS and AKI
Number of subjects: 48
Study 22875659 — intervention group
Group type: EXPERIMENTAL
Intervention: uKIM‐1 on day 7 in preterm infants with RDS and AKI
Number of subjects: 48
Study 21199658 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol administration
Number of subjects: 0
Study 21199658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20008240 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 0
Study 20008240 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront or debulking regimens
Number of subjects: 0
Study 20008240 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning regimen for ASCT
Number of subjects: 0
Study 20008240 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance or consolidation therapies
Number of subjects: 0
Study 20008240 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with novel agents
Number of subjects: 0
Study 20008240 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic transplantation
Number of subjects: 0
Study 17442550 — intervention group
Group type: EXPERIMENTAL
Intervention: Antalgics, antipyretics, and NSAIDs
Number of subjects: 0
Study 17442550 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs (aspirin, ibuprofen)
Number of subjects: 0
Study 17442550 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (acetaminophen)
Number of subjects: 0
Study 17442550 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal history of atopy and mean age ≥ 8 years
Number of subjects: 0
Study 15333723 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium, high-potassium diet (LNAHK)
Number of subjects: 94
Study 15333723 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium diet (HC)
Number of subjects: 94
Study 15333723 — intervention group
Group type: COMPARATOR
Intervention: Moderate-sodium, high-potassium, high-calcium DASH-type diet (OD)
Number of subjects: 94
Study 11772663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) steroid plus oral placebo
Number of subjects: 70
Study 11772663 — intervention group
Group type: COMPARATOR
Intervention: Oral steroid plus IM placebo
Number of subjects: 70
Study 9833199 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 0
Study 9833199 — intervention group
Group type: COMPARATOR
Intervention: Outpatient therapy, drop-in center, and brokered case management
Number of subjects: 0
Study 7641674 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 94
Study 7641674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 2504593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg)
Number of subjects: 0
Study 2504593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 g)
Number of subjects: 0
Study 2504593 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ofloxacin and cefotaxime
Number of subjects: 0
Study 341901 — intervention group
Group type: EXPERIMENTAL
Intervention: fluocortin butylester (Vaspit) in cream, ointment, and fatty ointment
Number of subjects: 1705
Study 341901 — intervention group
Group type: COMPARATOR
Intervention: fluocortolone (Ultralan) caproate or pivalate
Number of subjects: 1705
Study 341901 — intervention group
Group type: COMPARATOR
Intervention: hydrocortisone acetate
Number of subjects: 1705
Study 30613999 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner present
Number of subjects: 102
Study 30613999 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental activation (thinking about partner)
Number of subjects: 102
Study 30613999 — intervention group
Group type: COMPARATOR
Intervention: Control (thinking about their day)
Number of subjects: 102
Study 28407129 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate-containing dialysate plus a heparin-grafted membrane (CiTED)
Number of subjects: 25
Study 28407129 — intervention group
Group type: COMPARATOR
Intervention: Regional citrate anticoagulation (RCA)
Number of subjects: 25
Study 25997827 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mL ropivacaine (2 mg/mL) and 0.5 mL epinephrine (1 mg/mL)
Number of subjects: 116
Study 25997827 — intervention group
Group type: COMPARATOR
Intervention: 150 mL 0.9% saline (control)
Number of subjects: 116
Study 23652169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative colloid administration
Number of subjects: 2462
Study 23652169 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative colloid administration
Number of subjects: 2462
Study 21747002 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for occlusions after OAT publication
Number of subjects: 28780
Study 21747002 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for occlusions after guideline revisions
Number of subjects: 28780
Study 21747002 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI among hospitals consistently reporting diagnostic catheterizations after OAT publication
Number of subjects: 28780
Study 21747002 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI among hospitals consistently reporting diagnostic catheterizations after guideline revisions
Number of subjects: 28780
Study 19095860 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesiologists
Number of subjects: 61
Study 19095860 — intervention group
Group type: COMPARATOR
Intervention: CRNAs
Number of subjects: 61
Study 17111006 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + EAA + Glutamine (0.3 g/kg BW)
Number of subjects: 0
Study 17111006 — intervention group
Group type: COMPARATOR
Intervention: CHO + EAA (Control)
Number of subjects: 0
Study 15193484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 11388
Study 15193484 — intervention group
Group type: COMPARATOR
Intervention: Natural conception (control)
Number of subjects: 11388
Study 10657059 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol, 160 mg po as loading dose
Number of subjects: 5
Study 8773436 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (5 mg/kg over 20 min)
Number of subjects: 23
Study 8773436 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 23
Study 1835474 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical position (sitting or standing)
Number of subjects: 60
Study 1835474 — intervention group
Group type: COMPARATOR
Intervention: Horizontal position (side-lying or supine)
Number of subjects: 60
Study 6295286 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fibre diet
Number of subjects: 21
Study 6295286 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-fibre diet
Number of subjects: 21
Study 6295286 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fibre diet
Number of subjects: 21
Study 6295286 — intervention group
Group type: EXPERIMENTAL
Intervention: Bean diet
Number of subjects: 21
Study 6295286 — intervention group
Group type: COMPARATOR
Intervention: Exercise (prescribed level)
Number of subjects: 21
Study 31663814 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific sensitivity during physical function testing
Number of subjects: 260
Study 31663814 — intervention group
Group type: EXPERIMENTAL
Intervention: No pain group
Number of subjects: 260
Study 31663814 — intervention group
Group type: EXPERIMENTAL
Intervention: Better and unchanged groups
Number of subjects: 260
Study 31138290 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D display system
Number of subjects: 108
Study 31138290 — intervention group
Group type: COMPARATOR
Intervention: 4K display system
Number of subjects: 108
Study 28743247 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel monotherapy (80 mg/m2 weekly, 3 weeks on, 1 week off)
Number of subjects: 60
Study 28743247 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus sorafenib (400 mg orally, twice a day, starting dose of 200 mg)
Number of subjects: 60
Study 26158573 — intervention group
Group type: EXPERIMENTAL
Intervention: Field grading by trained trachoma graders
Number of subjects: 269
Study 26158573 — intervention group
Group type: COMPARATOR
Intervention: Photographic review by trained trachoma graders
Number of subjects: 269
Study 26158573 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus grade from photographic graders
Number of subjects: 269
Study 24612097 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcosine
Number of subjects: 30
Study 24612097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22298569 — intervention group
Group type: EXPERIMENTAL
Intervention: WR(+) - wheat/rye bread with in situ‐produced AXOS (180 g/d)
Number of subjects: 27
Study 22298569 — intervention group
Group type: COMPARATOR
Intervention: W(‐) - refined wheat flour bread without AXOS (180 g/d)
Number of subjects: 27
Study 20570218 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy with (125)I seed implants, prescription dose of 145 Gy.
Number of subjects: 43
Study 20570218 — intervention group
Group type: COMPARATOR
Intervention: Brachytherapy with (125)I seed implants in non-small prostate volume patients, 120 patients in total.
Number of subjects: 43
Study 17612998 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week workbook-based intervention
Number of subjects: 203
Study 17612998 — intervention group
Group type: COMPARATOR
Intervention: Normal care (control)
Number of subjects: 203
Study 16230487 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless valve
Number of subjects: 190
Study 16230487 — intervention group
Group type: COMPARATOR
Intervention: Stented valve
Number of subjects: 190
Study 12234037 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (50% of peak oxygen uptake, dual-cycle ergometry)
Number of subjects: 67
Study 12234037 — intervention group
Group type: COMPARATOR
Intervention: Post-exposure rest (control group)
Number of subjects: 67
Study 10401537 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive condition (Study 1)
Number of subjects: 128
Study 10401537 — intervention group
Group type: COMPARATOR
Intervention: Nonsupportive condition (Study 1)
Number of subjects: 128
Study 10401537 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly supportive condition (Study 2)
Number of subjects: 128
Study 10401537 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive condition (Study 2)
Number of subjects: 128
Study 10401537 — intervention group
Group type: COMPARATOR
Intervention: Nonsupportive condition (Study 2)
Number of subjects: 128
Study 7575710 — intervention group
Group type: EXPERIMENTAL
Intervention: DAB486IL-2
Number of subjects: 45
Study 7575710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 2688344 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ranitidine (50 mg every 6 hours for 72 hours from the skin incision)
Number of subjects: 24
Study 2688344 — intervention group
Group type: COMPARATOR
Intervention: Control (no ranitidine)
Number of subjects: 24
Study 1112949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propranolol (0.2 mg per kilogram)
Number of subjects: 10
Study 1112949 — intervention group
Group type: COMPARATOR
Intervention: Control SGaw
Number of subjects: 10
Study 1112949 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol treatment
Number of subjects: 10
Study 31548793 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task obstacle crossing (DTOC) training
Number of subjects: 22
Study 31548793 — intervention group
Group type: COMPARATOR
Intervention: Single-task obstacle crossing (STOC) training
Number of subjects: 22
Study 29180182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilomedin
Number of subjects: 71
Study 29180182 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oxygen
Number of subjects: 71
Study 29180182 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended warming
Number of subjects: 71
Study 29180182 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 71
Study 26925905 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene cover
Number of subjects: 96
Study 26925905 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposic ointment
Number of subjects: 96
Study 26925905 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial tear drop
Number of subjects: 96
Study 26925905 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 96
Study 23500312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 245
Study 23500312 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy
Number of subjects: 245
Study 21223250 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced chemotherapy (standard risk; SR)
Number of subjects: 171
Study 21223250 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy (medium risk; MR)
Number of subjects: 171
Study 19895208 — intervention group
Group type: EXPERIMENTAL
Intervention: ddI/3TC with efavirenz (EFZ)
Number of subjects: 107
Study 19895208 — intervention group
Group type: EXPERIMENTAL
Intervention: ddI/3TC with nevirapine (NVP)
Number of subjects: 107
Study 19895208 — intervention group
Group type: COMPARATOR
Intervention: Standard short-course anti-TB treatment (2EHRZ3/4RH3)
Number of subjects: 107
Study 19895208 — intervention group
Group type: EXPERIMENTAL
Intervention: ddI/3TC with either nevirapine or efavirenz
Number of subjects: 107
Study 19895208 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 107
Study 19895208 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI mutations
Number of subjects: 107
Study 21325437 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary glycemic load (GL) for single foods
Number of subjects: 134
Study 21325437 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary glycemic load (GL) for mixed meals
Number of subjects: 134
Study 21325437 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate content alone for single foods
Number of subjects: 134
Study 21325437 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate content alone for mixed meals
Number of subjects: 134
Study 16052108 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg/kg over 15 min followed by 0.2 microg x kg x h infusion)
Number of subjects: 64
Study 16052108 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (1 mg/kg) with midazolam (0.05 mg/kg)
Number of subjects: 64
Study 16052108 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (0.1-0.2 mg intravenous on demand)
Number of subjects: 64
Study 16052108 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 64
Study 16052108 — intervention group
Group type: COMPARATOR
Intervention: Meperidine with midazolam
Number of subjects: 64
Study 16052108 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 64
Study 12447733 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir (10 mg inhaled once daily for 10 days)
Number of subjects: 1291
Study 12447733 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inhaled once daily for 10 days)
Number of subjects: 1291
Study 12447733 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 1291
Study 9845131 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5FU) and cisplatin (CDDP) chemotherapy
Number of subjects: 156
Study 9845131 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 156
Study 8082346 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg bolus injection of alteplase over 15 min (maximum dose 50 mg)
Number of subjects: 53
Study 8082346 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of alteplase over 2 h
Number of subjects: 53
Study 8082346 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 53
Study 2658856 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training with a Triflow II inspirometer
Number of subjects: 22
Study 2658856 — intervention group
Group type: COMPARATOR
Intervention: Placebo training with a mini peak flow meter
Number of subjects: 22
Study 4888353 — intervention group
Group type: EXPERIMENTAL
Intervention: Two weeks' treatment with an appropriate antibacterial drug
Number of subjects: 0
Study 4888353 — intervention group
Group type: EXPERIMENTAL
Intervention: Six weeks' treatment with an appropriate antibacterial drug
Number of subjects: 0
Study 4888353 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 0
Study 4888353 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 0
Study 11486102 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-9
Number of subjects: 39
Study 11486102 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-2
Number of subjects: 39
Study 30627826 — intervention group
Group type: EXPERIMENTAL
Intervention: Six bouts of exercise each separated by 48 hours
Number of subjects: 28
Study 30627826 — intervention group
Group type: COMPARATOR
Intervention: Three bouts of exercise with 48 hours between the first two bouts and 8 days between the second and third bouts
Number of subjects: 28
Study 29097272 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor-assisted problem-solving
Number of subjects: 132
Study 29097272 — intervention group
Group type: COMPARATOR
Intervention: Internet resource comparison
Number of subjects: 132
Study 29097272 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with impairments
Number of subjects: 132
Study 29097272 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants identified as impaired
Number of subjects: 132
Study 26616256 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational programme for parents
Number of subjects: 134
Study 26616256 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured educational programme)
Number of subjects: 134
Study 26616256 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid use
Number of subjects: 134
Study 24483841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle Cell Disease (SCD) patients
Number of subjects: 107
Study 24483841 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta Thalassemia Major (β‐TM) patients
Number of subjects: 107
Study 24483841 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta Thalassemia Intermedia (β‐TI) patients
Number of subjects: 107
Study 24483841 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 107
Study 22548394 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumetasone ointment plus 308-nm excimer laser therapy
Number of subjects: 40
Study 22548394 — intervention group
Group type: COMPARATOR
Intervention: 308-nm excimer laser monotherapy
Number of subjects: 40
Study 19793378 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg/day
Number of subjects: 120
Study 19793378 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tamsulosin 0.2 mg/day and dutasteride 0.5 mg/day
Number of subjects: 120
Study 19793378 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg/day (alpha‐blocker group)
Number of subjects: 120
Study 17693178 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (target international normalised ratio 2‐3)
Number of subjects: 973
Study 17693178 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (75 mg per day)
Number of subjects: 973
Study 17693178 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 973
Study 17693178 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 973
Study 15165409 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic remedy (LM potency, 1/50,000 dilution)
Number of subjects: 62
Study 15165409 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plain solvent)
Number of subjects: 62
Study 15165409 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic remedy
Number of subjects: 62
Study 12194509 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step protocol
Number of subjects: 10
Study 12194509 — intervention group
Group type: COMPARATOR
Intervention: Three-step protocol
Number of subjects: 10
Study 9797360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500-750 mg twice a day)
Number of subjects: 83
Study 9797360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 9797360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 83
Study 8106700 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (titrated to a mean maximal dose of 87 mg/day)
Number of subjects: 50
Study 2818394 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg, t.i.d.)
Number of subjects: 12
Study 2818394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 46963 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fibre-containing breakfast cereal (double the normal fibre intake)
Number of subjects: 0
Study 46963 — intervention group
Group type: COMPARATOR
Intervention: Breakfast cereal containing negligible amounts of dietary fibre (control)
Number of subjects: 0